Search results

1321 results

Sorted by Relevance . Sort by Date

  1. Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation (TA355)

    Evidence-based recommendations on edoxaban (Lixiana) for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation (AF)

  2. Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab (TA357)

    Evidence-based recommendations on pembrolizumab (Keytruda) for treating advanced melanoma after disease progression with ipilimumab in adults

  3. Tolvaptan for treating autosomal dominant polycystic kidney disease (TA358)

    Evidence-based recommendations on tolvaptan (Jinarc) for treating autosomal dominant polycystic kidney disease (ADPKD)

  4. Vedolizumab for treating moderately to severely active ulcerative colitis (TA342)

    Evidence-based recommendations on vedolizumab (Entyvio) for treating moderately to severely active ulcerative colitis in adults

  5. Myocardial perfusion scintigraphy for the diagnosis and management of angina and myocardial infarction (TA73)

    Evidence-based recommendations on myocardial perfusion scintigraphy (MPS) for diagnosing and managing angina and myocardial infarction (MI)

  6. Pre-hospital initiation of fluid replacement therapy in trauma (TA74)

    Evidence-based recommendations on giving intravenous (IV) fluid replacement therapy for people with serious injuries before reaching hospital

  7. Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C (TA75)

    Evidence-based recommendations on interferon alfa (pegylated and non-pegylated) and ribavirin for treating chronic hepatitis C

  8. Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia (TA77)

    Evidence-based recommendations using zolpidem and zopiclone (the Z-drugs) for the short-term management of insomnia (sleeplessness) in adults

  9. Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer (TA660)

    Evidence-based recommendations on darolutamide (Nubeqa) for treating hormone-relapsed prostate cancer in adults at high risk of developing metastatic disease

  10. Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma (TA661)

    Evidence-based recommendations on pembrolizumab (Keytruda) for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) in a

  11. Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia (TA663)

    Evidence-based recommendations on venetoclax (Venclyxto) with obinutuzumab for untreated chronic lymphocytic leukaemia in adults

  12. Liraglutide for managing overweight and obesity (TA664)

    Evidence-based recommendations on liraglutide (Saxenda) for managing overweight and obesity alongside a reduced-calorie diet and increased physical activity in

  13. Larotrectinib for treating NTRK fusion-positive solid tumours (TA630)

    Evidence-based recommendations on larotrectinib (Vitrakvi) for treating neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumours in adults and

  14. Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer (TA638)

    Evidence-based recommendations on atezolizumab (Tecentriq) for untreated extensive-stage small-cell lung cancer in adults

  15. Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma (TA666)

    Evidence-based recommendations on atezolizumab (Tecentriq) with bevacizumab (Avastin) for treating advanced or unresectable hepatocellular carcinoma in adults

  16. Caplacizumab with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura (TA667)

    Evidence-based recommendations on caplacizumab (Cablivi) with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic

  17. Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer (TA653)

    Evidence-based recommendations on osimertinib (Tagrisso) for treating epidermal growth factor receptor (EGFR) T790M mutation-positive locally advanced or

  18. Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer (TA654)

    Evidence-based recommendations on osimertinib (Tagrisso) for untreated locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive

  19. Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy (TA655)

    Evidence-based recommendations on nivolumab (Opdivo) for advanced squamous non-small-cell lung cancer in adults after chemotherapy

  20. Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma (TA658)

    Evidence-based recommendations on isatuximab (Sarclisa) with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma in adults

  21. Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant (TA640)

    Evidence-based recommendations on treosulfan (Trecondi) with fludarabine for conditioning treatment before allogeneic haematopoietic stem cell transplant for

  22. Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma (TA641)

    Evidence-based recommendations on brentuximab vedotin (Adcetris) with cyclophosphamide, doxorubicin and prednisone for untreated systemic anaplastic large cell

  23. Gilteritinib for treating relapsed or refractory acute myeloid leukaemia (TA642)

    Evidence-based recommendations on gilteritinib (Xospata) for relapsed or refractory FLT3-mutation-positive acute myeloid leukaemia in adults

  24. Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer (TA643)

    Evidence-based recommendations on entrectinib (Rozlytrek) for ROS1-positive advanced non-small-cell lung cancer (NSCLC) in adults who have not had ROS1

  25. Entrectinib for treating NTRK fusion-positive solid tumours (TA644)

    Evidence-based recommendations on entrectinib (Rozlytrek) for treating neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumours in adults and

  26. Avelumab with axitinib for untreated advanced renal cell carcinoma (TA645)

    Evidence-based recommendations on avelumab (Bavencio) with axitinib (Inlyta) for untreated advanced renal cell carcinoma in adults

  27. Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma (TA649)

    Evidence-based recommendations on polatuzumab vedotin (Polivy) with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma

  28. Pembrolizumab with axitinib for untreated advanced renal cell carcinoma (TA650)

    Evidence-based recommendations on pembrolizumab (Keytruda) with axitinib (Inlyta) for untreated advanced renal cell carcinoma in adults

  29. Human growth hormone (somatropin) in adults with growth hormone deficiency (TA64)

    Evidence-based recommendations on human growth hormone (somatropin; Genotropin, Humantrope, Norditropin, Saizen) in adults with growth hormone deficiency

  30. Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza (TA158)

    Evidence-based recommendations on oseltamivir (Tamiflu), amantadine (Lysovir, Symmetrel) and zanamivir (Relenza) to prevent influenza (flu)